Publication | Closed Access

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation

Breast OncologyCancer ImmunosurveillanceMedicineMelanomaImmunologyImmune Response AugmentationPathologyImmune Checkpoint InhibitorBreast CancerFamily AImmunotherapyOncologyTumor MicroenvironmentTumor BiologyBimodality Index